Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1,Condition 2,Condition 3 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",blood insulin amount,,RS:0001303,F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj,male,211 days,11,,CMO:0000358,serum insulin level,,,,0.000339,mg/dl,0.0,1.0E-4,MMO:0000113,oral glucose tolerance test,,0.0,"ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN)",oral glucose,0,min,"specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) ",67478,specific pathogen-free condition (for 210 days),fasting (for 1 days),"glucose solution, 2.8M (2 g/kg) " 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",blood free fatty acid amount,,RS:0001303,F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj,male,218 days,11,,CMO:0000547,serum free fatty acids level,,,,0.68,mmol/l,0.045,0.1492,MMO:0000308,serum free fatty acid analysis,,0.0,"Wako Pure Chemicals, Tokyo, Japan",,,days,specific pathogen-free condition (for 210 days) then fasting (for 1 days),67498,specific pathogen-free condition (for 210 days),fasting (for 1 days), 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",epididymal fat pad mass,,RS:0001303,F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj,male,218 days,11,,CMO:0000658,epididymal fat pad weight to body weight ratio,,,,2.08,%,0.05,0.1658,MMO:0000005,post excision weight measurement,,0.0,,,,,specific pathogen-free condition (for 210 days) then fasting (for 1 days),67494,specific pathogen-free condition (for 210 days),fasting (for 1 days), 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",retroperitoneal fat pad mass,,RS:0001303,F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj,male,218 days,11,,CMO:0000635,retroperitoneal fat pad weight to body weight ratio,,,,8.8,%,0.3,0.995,MMO:0000005,post excision weight measurement,,0.0,,,,,specific pathogen-free condition (for 210 days) then fasting (for 1 days),67474,specific pathogen-free condition (for 210 days),fasting (for 1 days), 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",retroperitoneal fat pad mass,,RS:0001303,F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj,male,218 days,11,,CMO:0000356,retroperitoneal fat pad weight,,,,8.8,g,0.3,0.995,MMO:0000005,post excision weight measurement,,,,,,,specific pathogen-free condition (for 210 days) then fasting (for 1 days),12801,specific pathogen-free condition (for 210 days),fasting (for 1 days), 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",blood glucose amount,,RS:0001303,F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj,male,211 days,11,,CMO:0000046,blood glucose level,,,,87.7,mg/dl,3.2,10.6132,MMO:0000113,oral glucose tolerance test,,0.0,"ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN)",oral glucose,0,min,"specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) ",12798,specific pathogen-free condition (for 210 days),fasting (for 1 days),"glucose solution, 2.8M (2 g/kg) " 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",blood triglyceride amount,,RS:0001303,F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj,male,218 days,11,,CMO:0000360,serum triglyceride level,,,,111.7,mg/dl,8.83,29.2858,MMO:0000136,serum triglyceride analysis,,0.0,"Wako Pure Chemicals, Tokyo, Japan",,,,specific pathogen-free condition (for 210 days) then fasting (for 1 days),13195,specific pathogen-free condition (for 210 days),fasting (for 1 days), 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",mesenteric fat pad mass,,RS:0001303,F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj,male,218 days,11,,CMO:0000355,mesenteric fat pad weight,,,,7.6,g,0.3,0.995,MMO:0000005,post excision weight measurement,,,,,,,specific pathogen-free condition (for 210 days) then fasting (for 1 days),12800,specific pathogen-free condition (for 210 days),fasting (for 1 days), 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",blood cholesterol amount,,RS:0001303,F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj,male,218 days,11,,CMO:0000363,serum total cholesterol level,,,,76.2,mg/dl,1.79,5.9368,MMO:0000132,serum total cholesterol measurement test,,0.0,"Wako Pure Chemicals, Tokyo, Japan",,,,specific pathogen-free condition (for 210 days) then fasting (for 1 days),12799,specific pathogen-free condition (for 210 days),fasting (for 1 days), 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",epididymal fat pad mass,,RS:0001303,F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj,male,218 days,11,,CMO:0000357,epididymal fat pad weight,,,,8.8,g,0.3,0.995,MMO:0000005,post excision weight measurement,,,,,,,specific pathogen-free condition (for 210 days) then fasting (for 1 days),12802,specific pathogen-free condition (for 210 days),fasting (for 1 days), 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",body mass,,RS:0001303,F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj,male,211 days,11,,CMO:0000012,body weight,,,,423.2,g,7.3,24.2114,MMO:0000016,body weighing method,,0.0,,oral glucose,0,min,"specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) ",12803,specific pathogen-free condition (for 210 days),fasting (for 1 days),"glucose solution, 2.8M (2 g/kg) " 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",mesenteric fat pad mass,,RS:0001303,F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj,male,218 days,11,,CMO:0000654,mesenteric fat pad weight to body weight ratio,,,,1.81,%,0.07,0.2322,MMO:0000005,post excision weight measurement,,0.0,,,,,specific pathogen-free condition (for 210 days) then fasting (for 1 days),67470,specific pathogen-free condition (for 210 days),fasting (for 1 days), 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",blood adiponectin amount,,RS:0001303,F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj,male,211 days,11,,CMO:0000583,serum adiponectin level,,,,2.75,ng/ml,0.2,0.6633,MMO:0000075,enzyme linked immunosorbent assay,,0.0,"ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN)",,,,specific pathogen-free condition (for 210 days) then fasting (for 1 days),67482,specific pathogen-free condition (for 210 days),fasting (for 1 days), 311,"Kose H, et al., Mamm Genome. 2007 Aug;18(8):609-15. Epub 2007 Aug 21.",blood leptin amount,,RS:0001303,F344.OLETF-(D7Rat18-D7Mit2)(D14Rat23-D14Rat12)/Tj,male,211 days,11,,CMO:0000780,serum leptin level,,,,5.82,ng/ml,0.59,1.9568,MMO:0000075,enzyme linked immunosorbent assay,,0.0,"ADVANTAGE II glucose monitor (Roche Diagnostics, Indianapolis, IN)",oral glucose,7,days,"specific pathogen-free condition (for 210 days) then fasting (for 1 days) then glucose solution, 2.8M (2 g/kg) ",67486,specific pathogen-free condition (for 210 days),fasting (for 1 days),"glucose solution, 2.8M (2 g/kg) "